Alnylam Pharmaceuticals, Inc. ALNY
Analyst Ratings
- Consensus
- Buy — 16 Buy · 4 Hold · 0 Sell (20 analysts)
- Avg. Price Target
- $368.90 (+54.1% upside)
Key Stats
- Today's Range
- $236.00 – $242.24
- 50-Day Range
- $197.81 – $380.00
- 52-Week Range
- $197.81 – $495.55
- Volume
- 854K shs
- Average Volume
- 1.70 million shs
- Market Cap
- $31.88 billion
- P/E Ratio
- 44.57
- Dividend Yield
- —
Valuation
- P/E Ratio
- 44.57
- Price / Book
- 23.54
- Price / Sales
- 6.64
Short Interest
- Short Interest
- 4.32%
- Days to Cover
- 8.44
Financials (TTM)
- Revenue
- $4.80 billion
- Net Income
- $733.11 million
- Net Margin
- 15.26%
- Return on Equity
- 54.14%
- Debt-to-Equity
- —
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Related Stocks
Compare head-to-head: ALNY vs LLY·ALNY vs JNJ·ALNY vs ABBV·ALNY vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.